In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Inducible myocardial ischemia due to obstructive coronary artery disease is associated with subclinical LV dysfunction in patients with stable angina

Session Poster Session 3

Speaker Danilo Neglia

Event : Heart Failure 2016

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session

Authors : C Caselli (Pisa,IT), V Lorenzoni (Pisa,IT), M Lombardi (San Donato Milanese,IT), R Sicari (Pisa,IT), AJ Scholte (Leiden,NL), J Knuuti (Turku,FI), SR Underwood (London,GB), A Clerico (Pisa,IT), M Emdin (Pisa,IT), D Neglia (Pisa,IT)

C Caselli1 , V Lorenzoni2 , M Lombardi3 , R Sicari1 , AJ Scholte4 , J Knuuti5 , SR Underwood6 , A Clerico2 , M Emdin7 , D Neglia7 , 1Institute of Clinical Physiology of CNR - Pisa - Italy , 2Scuola Superiore Sant'Anna - Pisa - Italy , 3IRCCS, Policlinico San Donato - San Donato Milanese - Italy , 4Leiden University Medical Center - Leiden - Netherlands , 5University of Turku and Turku University Hospital - Turku - Finland , 6Imperial College London - London - United Kingdom , 7Gabriele Monasterio Foundation - Pisa - Italy ,

On behalf: EVINCI study

European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 419

Background: Repetitive myocardial ischemia might impair LV function in patients with stable coronary artery macrovascular and/or microvascular disease (CAD). Purpose: To assess the relationship between inducible myocardial ischemia, presence of obstructive CAD and LV function in patients with stable angina. Methods: Clinical, functional and imaging data were collected in 362 patients (212 males, 150 females, mean age 60 ± 9 years) with stable angina and suspected CAD enrolled in the Evaluation of INtegrated Cardiac Imaging (EVINCI) study. All patients underwent echocardiography and circulating NT-proBNP measurements to assess LV function, stress imaging to detect myocardial ischemia and coronary computed tomography angiography (CCTA) to assess the presence of obstructive CAD (>50% stenosis of a major coronary vessel). Only patients with LVEF ≥50% were included in this substudy. Results: LVEF was 60 [55-66] %, median [25-75 percentiles], and NT-proBNP was 60.7 [30.7-128.0] ng/L in the whole population. Patients were subdivided in 4 groups according to the presence/absence of myocardial ischemia and obstructive CAD. LVEF and NT-proBNP values are compared among groups in Figure 1. Patients with obstructive CAD+Ischemia had significantly lower LVEF and significantly higher NT-proBNP values than the other groups. At multivariate analysis including age, sex, cardiovascular risk factors, drugs, CTA and stress imaging results, presence of obstructive CAD+Ischemia was the only coronary pattern predicting both LVEF (Coefficient: - 0.119 ± 0.03 (SE), p < 0.0001 ) and NT-proBNP (0.512 ± 0.15, p = 0.0009) values. Conclusions: In patients with stable angina, inducible myocardial ischemia caused by macrovascular obstructive CAD is associated with early impairment of LV function.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are